A
ALVO
vs
S&P 500
S&P 500
Over the past 12 months, ALVO has underperformed S&P 500, delivering a return of -69% compared to the S&P 500's +13% growth.
Stocks Performance
ALVO vs S&P 500
Performance Gap
ALVO vs S&P 500
Performance By Year
ALVO vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Alvotech SA
Glance View
In the fiercely competitive world of pharmaceuticals, Alvotech SA has carved out a distinct niche as a specialist in developing biosimilars—essentially highly similar alternatives to already approved biological medicines. Based in Iceland, the company was founded by Robert Wessman, renowned for his successful ventures in the pharmaceutical industry. Alvotech strives to not only make crucial medications more accessible but to also alleviate the strain of high drug costs on healthcare systems worldwide. With its ardent focus on quality and efficacy, Alvotech's innovative research and development strategies underline its commitment to replicating complex biologics, ensuring they are more affordable without compromising on safety and effectiveness. Alvotech’s business model is intricately woven into the fabric of collaboration and partnership. Rather than attempting to market its products independently, Alvotech aligns with a network of global partners for commercialization and distribution, allowing the company to reach diverse markets efficiently. This approach not only widens their reach but also minimizes the cost and time associated with entering new geographical territories. Alvotech generates revenue by selling these biosimilars, capitalizing on the expiration of patents on original biologic drugs. In doing so, it provides healthcare providers and patients with cost-effective options, positioning itself as a valuable player in the increasingly essential biosimilar market.
